Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Jan-Feb;24(1):25-29.
doi: 10.1016/j.bjid.2019.10.011. Epub 2019 Nov 21.

Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes

Giovana Rossato  1 , Cristiane Valle Tovo  2 , Paulo Roberto Lerias de Almeida  3
Affiliations
Observational Study

Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes

Giovana Rossato et al. Braz J Infect Dis. 2020 Jan-Feb.

Abstract

Background: To analyze the effectiveness and the safety of Sofosbuvir-based regimens to treat patients with chronic hepatitis C virus (HCV) infection and chronic kidney disease (CKD).

Methods: A retrospective, observational study in patients with chronic HCV infection and CKD treated with Sofosbuvir-based regimens was performed. Liver fibrosis, comorbidities, HCV genotype and sustained virological resposnse (SVR) at 12th week post-treatment were evaluated. Kidney function was accessed by serum creatinine and glomerular filtration rate (GFR). The assumed level of significance was 5 %.

Results: Thirty-five patients were treated. The mean age was 52.1±10.9 years, 19 (54.3 %) were women, 32 (91.4 %) were already kidney transplanted and 3 (8.6 %) were on hemodialysis. The SVR by intention to treat was 88.6 %. The mean GFR was 65.8±28.6 and 63.7±28.3ml/min pre- and post-treatment respectively (p>0.05). Treatment was interrupted in 1 (2.85 %) patient due to anemia and in 2 (5.7 %) due to loss of kidney function.

Conclusion: Sofosbuvir-based regimens are effective to treat HCV in patients with CKD. In patients with mild CKD this type of therapy seems to be safe.

Keywords: Daclatasvir; Direct-acting antiviral; Hemodialysis; Kidney transplantion; Sofosbuvir.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Comparation between the stages of CKD pre, post and 3 months after the end of treatment. (p = 0459 McNemar test).
See this image and copyright information in PMC

References

    1. Jadoul M., Bieber B.A., Martin P., Akiba T., Nwankwo C., Arduino J.M., Goodkin D.A., Pisoni R.L. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int. 2019;4:939–947. - PubMed
    1. Pereira L.M.M.B., Martelli C.M., Moreira R.C., Merchan-Hamman E., Stein A.T., Cardoso R.M.A., et al. Prevalence and risk factors of hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis. 2013;1:60. - PMC - PubMed
    1. Sesso R.C., Lopes A.A., Thomé F.S., Lugon J.R., Martins C.T. Brazilian Chronic Dialysis Census 2014. J Bras Nefrol. 2016;38:54–61. - PubMed
    1. Chen Y.C., Li C.Y., Tsai S.J., Chen Y.C. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World J Clin case. 2019;11:1270–1281. - PMC - PubMed
    1. Gordon C.E., Berenguer M.C., Doss W., Fabrizi F., Izopet J., Jha V., et al. Prevention, diagnosis, evaluation, and treatment of hepatitis C virus infection in chronic kidney disease: synopsis of the kidney disease: Improving Global Outcomes 2018 Clinical Practice Guideline. Ann Intern Med. 2019;171:496–504. - PubMed

Publication types

MeSH terms